The CD163/TWEAK/Fn14 axis: A potential therapeutic target for alleviating inflammatory bone loss

Ji-kun Qian,Yuan Ma,Xuan Huang,Xiao-ran Li,Ya-fei Xu,Zi-ying Liu,Yuan Gu,Ke Shen,Liang-jie Tian,Yu-tian Wang,Ning-ning Cheng,Bing-sheng Yang,Kui-yuan Huang,Yu Chai,Guan-qiao Liu,Nai-qian Cui,Song-yun Deng,Nan Jiang,Dao-rong Xu,Bin Yu
DOI: https://doi.org/10.1016/j.jot.2024.09.002
IF: 6.6
2024-10-06
Journal of Orthopaedic Translation
Abstract:Objective Osteoclast (OC) over-activation is an important cause of bone loss that is strongly correlated with inflammation. Although the CD163/TWEAK/Fn14 axis has been implicated in several inflammatory pathologies, its contributions to inflammatory bone loss remain poorly understood. This study aimed to evaluate the interaction of the CD163/TWEAK/Fn14 axis with OC in inflammatory bone loss. Methods To assess the role of CD163 in bone homeostasis, we characterized the bone phenotypes of CD163-deficient mice and their wild-type littermates. CD163 and TWEAK levels were evaluated in the bone marrow of mice with LPS-induced bone loss and individuals with rheumatoid arthritis (RA). Bone mass changes were assessed using uCT and histology following supplementation with recombinant mouse CD163 protein (rCD163) or blockade of TWEAK/Fn14 signaling in CD163-deficient mice and mice with LPS-induced bone loss. The impact of CD163/TWEAK on OC differentiation and bone resorption capacity was analyzed in vitro . Results CD163 deficiency caused decreased bone mass and increased OC abundance. Lower CD163 expression and higher TWEAK expression were observed in the bone marrow of mice with LPS-induced bone loss and individuals with RA. TWEAK, mainly derived from CD68 + macrophages, was responsible for bone loss, and supplementing rCD163 or blocking TWEAK/Fn14 signaling contributed to rescue bone loss. TWEAK/Fn14 synergistically promoted RANKL-dependent OC differentiation and bone resorption capability through downstream mitogen-activated protein kinases (MAPK) signaling, while the pro-osteoclastic effect of TWEAK was suppressed by CD163. Conclusion Our findings suggest that the CD163/TWEAK/Fn14 axis is a potential therapeutic target for inflammatory bone loss by regulating osteoclastogenesis.
orthopedics
What problem does this paper attempt to address?